Publications


AIMSPRO has been the subject of a number of peer-reviewed publications, largely in abstract form, which are set out below. An oral presentation describing the experience of AIMSPRO in four cases of treatment-resistant Myasthenia Gravis was recently delivered at the World Congress of Internal Medicine.



Published Peer-Reviewed Papers

  • Quillinan N, McIntosh D, Haq S, Denton CP A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy. Arthritis and Rheumatism Vol 64, Supplement S10, Page S297, Abstract 693
  • Youl BD, White SDT, Cadogan M, Maizels DW, Brooman IC and Dalgleish AG. Goat serum product 'Aimspro' restores conduction in demyelinated human optic nerve fibres. Journal of Clinical Neuroscience. 15th March 2006.
  • Mackenzie R, Kiernan M, Mackenzie D, Youl BD. Hyperimmune goat serum for amyotrophic lateral sclerosis. Journal of Clinical Neuroscience 2006;13:1037
  • Mackenzie R. Follow-up study of hyper-immune goat serum (AIMSPRO®) for amyotrophic lateral sclerosis (letter). Journal of Clinical Neuroscience 2009;16:1508


Published Abstracts

  • Moore C, Haq M, Haq S Clinical Benefits with Aimspro® in Progessive Multiple Sclerosis: Open Label Study
  • Haq S, Ahtoniemi T, Oksman J, Lehtimäki K, Cerrada-Gimenez M, Westlake A, Moore C, Haq M, Vartiainen N, McIntosh D The role of stabilized neuropeptides derived from hyperimmune caprine sera (HICS) in motor neuron disease – implications for a novel therapeutic strategy
  • Quillinan N, McIntosh D, Haq S, Denton CP A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
  • Quillinan N, McIntosh D, Haq S, Denton C A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum as Potential Treatment for Established Diffuse Cutaneous Systemic Sclerosis
  • Angus-Leppan H, Youl B. Hyperimmune caprine serum against HIV lysate is a potential treatment for myasthenia gravis. Internal Medicine Journal 2010;40 (Suppl. 1):64
  • Burke G, Cavey A, Matthews P, Palace J. The evaluation of a novel 'goat serum' (Aimspro)in Multiple Sclerosis. J Neurology Neurosurgery and Psychiatry 2005;76:1326
  • Mackenzie R, Kiernan M, McKenzie D, Youl BD (2005). Follow-up study of hyperimmune goat serum in a patient with Amyotrophic Lateral Sclerosis (abstract). 16th International Symposium on ALS/MND, Dublin
  • Moore CEG, Hannan R, McIntosh D. In vivo, human peripheral nerve strength duration time constant changes with Aimspro implicate altered sodium channel function as a putative mechanism of action.
  • Journal of the Neurological Sciences. 2005; Vol 238: Suppl. 1. pS238. (World Congress of Neurology, 2005) Moore CEG, Youl BD, Moore WMH, Orrel R (2005). Multimodality neurophysiological testing in the assessment of a novel therapeutic approach to Leukodystrophy and Charcot-Marie-Tooth disease (abstract). BSCN meeting, Sheffield, 18th March 2005 – doi: 10.1016/j.clinph.2006.07.264


Selected Publications

  • Youl BD, White SDT, McIntosh D, Cadogan M, Dalgleish AG, Ginsberg L. Hyperimmune serum reverses conduction block in demyelinated human optic nerve and peripheral nerve fibres (abstract). Joint Sino-British Neurology meeting, Beijing. J Neurology Neurosurgery and Psychiatry 2004;76:615
  • Youl BD, Ginsberg L (2004). Goat serum product AIMSPRO shows promise as an effective treatment in CIDP (abstract). BSCN meeting, National Hospital, London, 21st October 2004 - doi: 10.1016/j.clinph.2006.07.249
  • Youl BD, Crum J. Clinical Improvement in Krabbe's Disease case treated with hyperimmune goat serum product Aimspro. Journal of the Neurological Sciences. 2005; Vol 238: Suppl. 1. pS110. (World Congress of Neurology, 2005)
  • Youl BD, Angus-Leppan H, Hussein N, Brooman I, Fitzsimons RB. Rapid and sustained response to hyperimmune goat serum product in a patient with Myaesthenia Gravis. Journal of the Neurological Sciences. 2005; Vol 238: Suppl. 1. pS177. (World Congress of Neurology, 2005)
  • Youl BD, Orrell R. Goat serum product Aimspro produces sustained improvement in muscle power in a patient with Fascioscapulohumeral Dystrophy. Journal of the Neurological Sciences. 2005; Vol 238: Suppl. 1. pS169. (World Congress of Neurology, 2005)
  • Youl BD, White SDT, Cadogan MA, Dalgleish AG (2004). Goat Serum product restores conduction in demyelinated human optic nerve fibres (abstract). J Neurology Neurosurgery and Psychiatry 2005;76:615 (doi: 10.1016/j.clinph.2006.07.239)
  • Youl BD, McIntosh DP, Martin C, Mackenzie RA, Bailey S (2010). Hyperimmune caprine serum (AIMSPRO) and neuroinflammation (abstract). Journal of Peripheral Nerve doi: 10.1111/j.1529-8027.2010.00256.x
  • Youl BD, Mackenzie RA, Bailey S Hyperimmune caprine serum against HIV-lysate (AIMSPRO), a TNF-α suppressing agent, may modify clinical and respiratory functions in ALS, presented at the 21st International Symposium on ALS/MND, held in the Orlando, Florida, United States in December 2010
  • Moore C, Haq M, Haq S Clinical Benefits reported with AIMSPRO® treatment in progressive multiple sclerosis: Open-label observations
  • Haq S, Ahtoniemi T, Oksman J, Lehtimäki K, Cerrada-Gimenez M, Westlake A, Moore C, Haq M, Vartiainen N, McIntosh D The role of stabilized neuropeptides derived from hyperimmune caprine sera (HICS) in motor neuron disease – implications for a novel therapeutic strategy
  • Quillinan N, McIntosh D, Haq S, Denton CP A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy (download poster)